Oragenics (NYSE American: OGEN) Explores CNS Asset Acquisition to Enhance Brain Health Pipeline
Expert Analysis Oragenics (NYSE American: OGEN) is strategically positioning itself within the central nervous system (CNS) therapeutic landscape by considering asset acquisitions that align with its proprietary intranasal delivery technology. This approach highlights the company’s commitment to advancing brain health and recovery indications, which complements its existing pipeline focused on brain-targeted treatments. The exploration of additional CNS assets holds potential for synergistic enhancements to Oragenics’ lead candidate ONP-002, potentially accelerating…








